Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?

Anthi BouchlaSotirios G PapageorgiouArgyris SymeonidisIoanna SakellariPanagiotis ZikosThomas P ThomopoulosEleftheria HatzimichaelAthanasios GalanopoulosNora-Athina VyniouIoannis KotsianidisVassiliki Pappa

Published in: Leukemia (2023)

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
acute myeloid leukemia
prognostic factors
peritoneal dialysis
patient reported outcomes